Keywords: Shire, Third quarter 2009 results, Adderall
Shire’s new drugs offset slumping Adderall in 3rd quarter 2009
Article | 2 November 2009
Shire, the UK’s third largest drugmaker, posted revenues from continuing operations for the three months to September 30, 2009 down 14% to $667.0 million (2008: $778.6 million), due to the decline in branded Adderall XR (amphetamine and dextroamphetamine), used to treat narcolepsy and attention deficit hyperactivity disorder (ADHD), following the launch of an authorized generic version by Teva in April 2009. However, core product sales increased by 20% to $531.6 million, noted the company, which saw its share price rise 4.7% to £10.72 on the day of the announcement, October 30.
Non GAAP operating income decreased 52% to $133.6 million. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
